Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Caplacizumab Improves Platelet Normalization Time, Reduces Mortality in Acquired TTP

Adding caplacizumab to standard of care for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) shortened the time to the normalization of platelet counts...

An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML

According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...

Apixaban AVERTs Cancer-Associated Venous Thromboembolism

In the randomized, placebo-controlled AVERT trial, investigators assessed the safety and efficacy of apixaban thromboprophylaxis in patients with cancer considered to be at intermediate-...

Is a Longer Schedule of Decitabine More Effective Than a 5-Day Schedule in Older...

For older patients with treatment-naïve acute myeloid leukemia (AML), research has suggested that a 10-day treatment schedule of the hypomethylating agent decitabine is associated...

Ibrutinib Plus Obinutuzumab Superior to Standard Chemoimmunotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia

Treatment with the regimen of ibrutinib plus obinutuzumab improved outcomes for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),...

Restrictive Transfusion Therapy Safe for Cardiac Surgery Patients

Setting higher hemoglobin (Hb) thresholds for red-cell transfusion therapy in patients undergoing cardiac surgery with a moderate to high risk of death was noninferior...

Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...

People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...

Emicizumab Prophylaxis Reduces Bleeding Events in Hemophilia A Without Inhibitors

Treatment with emicizumab was associated with lower bleeding rates, compared with no prophylaxis, in patients with hemophilia A without inhibitors, according to findings from...

No Added Benefit When Hydroxyurea Is Combined With Aspirin in Middle-Aged Patients With Essential...

Cytoreductive treatment with hydroxyurea has been shown to reduce the risk of thrombosis in patients with essential thrombocythemia (ET) and high-risk features, which include...

Researchers Identify Genetic Prognostic Predictors in Myeloproliferative Neoplasms

A team of European and American researchers have identified and characterized associations between specific genetic mutations and prognosis in patients with myeloproliferative neoplasms (MPNs),...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.